National Health (April 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026

PB 30 of 2026

I, Rebecca Richardson, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.

Dated 18 March 2026

REBECCA RICHARDSON

Assistant Secretary

PBS Listing, Pricing and Policy Branch

Technology Assessment and Access Division

Department of Health, Disability and Ageing

1 Name

(1) This instrument is the National Health (April 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026.

(2) This instrument may also be cited as PB 30 of 2026.

2 Commencement

This instrument commences on 1 April 2026.

3 Authority

This instrument is made under sections 99ACB, 99ACC and 99ACD of the National Health Act 1953.

4 Definitions

Note: A number of expressions used in this instrument are defined in Part VII the Act.

In this instrument:

Act means the National Health Act 1953.

Reduction day refers to 1 April 2026.

5 Brands of pharmaceutical item (not combination items) not subject to a price reduction

I determine under paragraph 99ACB(6A)(a) of the Act that the agreed price of the brand of pharmaceutical item specified in item 1 in the table in Part 1 of Schedule 1 that comes into force on the reduction day is to be equal to the approved ex‑manufacturer price, on the day before the determination day, of the listed brands of the existing item.

6 Single brands of pharmaceutical item (combination items) not subject to a price reduction

I determine under paragraph 99ACC(5C)(a) of the Act that the agreed price of the brand of pharmaceutical items specified in the table in Part 1 of Schedule 2 that comes into force on the reduction day is to be equal to the approved ex‑manufacturer price, on the day before the determination day, of the listed brands of the existing item.

7 Brands of pharmaceutical item (combination items) not subject to a price reduction

I determine under paragraph 99ACD(7A)(a) of the Act that the agreed price of the brand of pharmaceutical item specified in item 1 in the table in Part 1 of Schedule 3 that comes into force on the reduction day is to be equal to the approved ex‑manufacturer price, on the day before the determination day, of the listed brands of the existing item.

8 Brands of pharmaceutical item (combination items) subject to a lower price reduction than would otherwise apply

I determine under paragraph 99ACD(7A)(b) of the Act that the agreed price of the brand of pharmaceutical item specified in item 1 in the table in Part 1 of Schedule 4 that comes into force on the reduction day must not exceed the approved ex‑manufacturer price, on the day before the determination day, of the listed brands of the existing item, reduced by the percentage specified in column 3 of the table item in relation to the reduction day.

Schedule 1 Brands of pharmaceutical item (not combination items) not subject to a price reduction

Part 1

Column 1	Column 2
Item	Brand of pharmaceutical item
	Drug	Form	Manner of administration	Brand
1	Progesterone	Capsule 100 mg	Oral	Progesterone ADVZ 100

Schedule 2 Single brands of pharmaceutical item (combination items) not subject to a price reduction

Part 1

Column 1	Column 2
Item	Brand of pharmaceutical item
	Drug	Form	Manner of administration	Brand
1	Progesterone and estradiol	Pack containing 30 capsules progesterone 100 mg (micronised) and transdermal gel (pump pack) estradiol 750 micrograms (as hemihydrate) per 1.25 g dose, 64 doses	Oral/Transdermal	Estrogel Pro
2	Dapagliflozin with sitagliptin	Tablet containing 10 mg dapagliflozin (as propanediol monohydrate) with 100 mg sitagliptin (as phosphate monohydrate)	Oral	Sidapvia 10/100

Schedule 3 Brands of pharmaceutical item (combination items) not subject to a price reduction

Part 1

Column 1	Column 2
Item	Brand of pharmaceutical item
	Drug	Form	Manner of administration	Brand
1	Beclometasone with formoterol	Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 dose	Inhalation by mouth	Cipla Beclometasone/Formoterol 100/6

Schedule 4 Brands of pharmaceutical item (combination items) subject to a lower price reduction than would otherwise apply

Part 1

Column 1	Column 2				Column 3
Item	Brand of pharmaceutical item
	Drug	Form	Manner of administration	Brand	% Reduction
1	Beclometasone with formoterol	Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 dose	Inhalation by mouth	Cipla Beclometasone/Formoterol 200/6	1

Administered by Department of Health, Disability and Ageing

Interactions

Legislation content

Interactions

Authorises

All Versions